Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510417 | 0.83 | PIK3CA (0.42) | IRAK4ALDH1A1PIK3CA | |
| SCHEMBL2512573 | 0.82 | ADAM17 (0.39) | PRMT5WDR77ADAM17ALDH1A1ITGB3 | |
| SCHEMBL2509815 | 0.81 | BRD4 (0.41) | IRAK4ALDH1A1PIK3CA | |
| SCHEMBL2512685 | 0.76 | ADAM17 (0.40) | PRMT5WDR77ADAM17ALDH1A1ITGB3 | |
| SCHEMBL2510033 | 0.75 | EGFR (0.43) | PRMT5WDR77ADAM17ITGB3ITGA2B | |
| SCHEMBL2510813 | 0.74 | BRD9 (0.40) | PIK3CA | |
| SCHEMBL2509656 | 0.73 | PRMT5 (0.41) | PRMT5WDR77ADAM17ITGB3ITGA2B | |
| SCHEMBL2512018 | 0.73 | BRD9 (0.38) | ALDH1A1PIK3CA | |
| SCHEMBL2511082 | 0.72 | PIK3CA (0.41) | IRAK4ALDH1A1PIK3CA | |
| SCHEMBL2511076 | 0.71 | PRMT5 (0.37) | PRMT5WDR77ADAM17ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | claimed |
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | GRM3, GRIN2C, GRIN2B | PRMT5 1226/4885WDR77 2121/4885IRAK4 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.